Pfizer Corporation

Benjamin Dawson Stevens

Angel Guzman-Perez

Jeffrey Allen Pfefferkorn

Meihua Mike Tu

Kevin James Filipski

Mary Theresa Didiuk

Gary Erik Aspnes

Esther Cheng Yin Lee

Esther C Lee

Esther Cheng Lee

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R, R, R, A, A, A, A, L, B, B, Band Bare as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

Glucagon receptor modulators

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R, R, A, A, A, B, B, Band Bare as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

Quinolinyl glucagon receptor modulators

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R, R, A, A, A, B, B, Band Bare as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon. 

Growing community of inventors

Cambridge, MA, United States of America

Benjamin Dawson Stevens